Classifying new anti-tuberculosis drugs: rationale and future perspectives

Classifying new anti-tuberculosis drugs: rationale and future perspectives

The classification of anti-tuberculosis (TB) drugs is important as it helps the clinician to build an appropriate anti-TB regimen for multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB cases that do not fulfil the criteria for the shorter MDR-TB regimen. The World Health Organization...

Full description

Bibliographic Details
Main Authors: Simon Tiberi, Anna Scardigli, Rosella Centis, Lia D’Ambrosio, Marcela Muñoz-Torrico, Miguel Ángel Salazar-Lezama, Antonio Spanevello, Dina Visca, Alimuddin Zumla, Giovanni Battista Migliori, Jose A. Caminero Luna
Format: Article
Language:English
Published: Elsevier 2017-03-01
Series:International Journal of Infectious Diseases
Subjects:
Anti-TB drugs
MDR/XDR-TB
Fluoroquinolones
Linezolid
Bedaquiline
Delamanid ;
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971216312103

Internet

http://www.sciencedirect.com/science/article/pii/S1201971216312103

Similar Items